Pfizer’s abrocitinib clears first Phase III hurdle with ease

GlobalData anticipates abrocitinib to launch in 2020 and generate $1.5 billion in revenue by 2027 to become the leading JAK inhibitor treatment for atopic dermatitis.



  • Atopic dermatitis treatment 2020